<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: T-cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e>) accounts for 10% to 15% of newly diagnosed cases of childhood <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) </plain></SENT>
<SENT sid="1" pm="."><plain>Historically, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> patients have had a worse prognosis than other ALL patients </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: We reviewed the outcomes of 125 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> treated on Dana-Farber <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Institute (DFCI) ALL Consortium trials between 1981 and 1995 </plain></SENT>
<SENT sid="3" pm="."><plain>Therapy included four- or five-agent remission induction; consolidation therapy with <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="50858">corticosteroid</z:chebi>, <z:chebi fb="0" ids="50667">mercaptopurine</z:chebi>, and weekly high-dose asparaginase; and cranial radiation </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> patients were treated the same as high-risk B-progenitor ALL patients </plain></SENT>
<SENT sid="5" pm="."><plain>Fifteen patients with T-cell lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were also treated with the same high-risk regimen between 1981 and 2000 </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The 5-year event-free survival (EFS) rate for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> patients was 75% +/- 4% </plain></SENT>
<SENT sid="7" pm="."><plain>Fourteen of 15 patients with T-cell lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were long-term survivors </plain></SENT>
<SENT sid="8" pm="."><plain>There was no significant difference in EFS comparing patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> and B-progenitor ALL (P =.56), although <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> patients had significantly higher rates of induction failure (P &lt;.0001), and central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) relapse (P =.02) </plain></SENT>
<SENT sid="9" pm="."><plain>The median time to relapse in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> patients was 1.2 years versus 2.5 years in B-progenitor ALL patients (P =.001) </plain></SENT>
<SENT sid="10" pm="."><plain>There were no pretreatment characteristics associated with worse prognosis in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> patients fared as well as B-progenitor patients on DFCI ALL Consortium protocols </plain></SENT>
<SENT sid="12" pm="."><plain>Patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> remain at increased risk for induction failure, early relapse, and isolated <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> relapse </plain></SENT>
<SENT sid="13" pm="."><plain>Future studies should focus on the identification of and treatment for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> patients at high risk for treatment failure </plain></SENT>
</text></document>